Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing clinical data on anti-IgE, anti-IL-5 and other immunological pathways indicate these therapies to offer reduced exacer...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.983852/full |
| _version_ | 1811179237411913728 |
|---|---|
| author | Grzegorz Kardas Michał Panek Piotr Kuna Piotr Damiański Maciej Kupczyk |
| author_facet | Grzegorz Kardas Michał Panek Piotr Kuna Piotr Damiański Maciej Kupczyk |
| author_sort | Grzegorz Kardas |
| collection | DOAJ |
| description | Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing clinical data on anti-IgE, anti-IL-5 and other immunological pathways indicate these therapies to offer reduced exacerbation rates, improved lung function, greater asthma control and better quality of life. However, as several patients still do not achieve satisfactory clinical response with the antibodies available, many more biologics, aiming different immunological pathways, are under evaluation. This review summarizes recent data on existing and potential monoclonal antibodies in asthma. Recent advances have resulted in the registration of a new antibody targeting TSLP (tezepelumab), with others being under development. Some of the researched monoclonal antibodies (e.g. anti-IL-13 tralokinumab and lebrikizumab or anti-IL-17A secukinumab) have shown optimistic results in preliminary research; however, these have been discontinued in asthma clinical research. In addition, as available monoclonal antibody treatments have shown little benefit among patients with T2-low asthma, research continues in this area, with several antibodies in development. This article summarizes the available pre-clinical and clinical data on new and emerging drugs for treating severe asthma, discusses discontinued treatments and outlines future directions in this area. |
| first_indexed | 2024-04-11T06:32:29Z |
| format | Article |
| id | doaj.art-3817e538d1dc4d758cdb30731e8a498e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T06:32:29Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3817e538d1dc4d758cdb30731e8a498e2022-12-22T04:39:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-12-011310.3389/fimmu.2022.983852983852Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectivesGrzegorz KardasMichał PanekPiotr KunaPiotr DamiańskiMaciej KupczykPatients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing clinical data on anti-IgE, anti-IL-5 and other immunological pathways indicate these therapies to offer reduced exacerbation rates, improved lung function, greater asthma control and better quality of life. However, as several patients still do not achieve satisfactory clinical response with the antibodies available, many more biologics, aiming different immunological pathways, are under evaluation. This review summarizes recent data on existing and potential monoclonal antibodies in asthma. Recent advances have resulted in the registration of a new antibody targeting TSLP (tezepelumab), with others being under development. Some of the researched monoclonal antibodies (e.g. anti-IL-13 tralokinumab and lebrikizumab or anti-IL-17A secukinumab) have shown optimistic results in preliminary research; however, these have been discontinued in asthma clinical research. In addition, as available monoclonal antibody treatments have shown little benefit among patients with T2-low asthma, research continues in this area, with several antibodies in development. This article summarizes the available pre-clinical and clinical data on new and emerging drugs for treating severe asthma, discusses discontinued treatments and outlines future directions in this area.https://www.frontiersin.org/articles/10.3389/fimmu.2022.983852/fullasthmasevere asthmamonoclonal antibodiestezepelumabdupilumabbenralizumab |
| spellingShingle | Grzegorz Kardas Michał Panek Piotr Kuna Piotr Damiański Maciej Kupczyk Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives Frontiers in Immunology asthma severe asthma monoclonal antibodies tezepelumab dupilumab benralizumab |
| title | Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives |
| title_full | Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives |
| title_fullStr | Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives |
| title_full_unstemmed | Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives |
| title_short | Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives |
| title_sort | monoclonal antibodies in the management of asthma dead ends current status and future perspectives |
| topic | asthma severe asthma monoclonal antibodies tezepelumab dupilumab benralizumab |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.983852/full |
| work_keys_str_mv | AT grzegorzkardas monoclonalantibodiesinthemanagementofasthmadeadendscurrentstatusandfutureperspectives AT michałpanek monoclonalantibodiesinthemanagementofasthmadeadendscurrentstatusandfutureperspectives AT piotrkuna monoclonalantibodiesinthemanagementofasthmadeadendscurrentstatusandfutureperspectives AT piotrdamianski monoclonalantibodiesinthemanagementofasthmadeadendscurrentstatusandfutureperspectives AT maciejkupczyk monoclonalantibodiesinthemanagementofasthmadeadendscurrentstatusandfutureperspectives |